(KRTX)

業務介紹

卡魯納治療公司(Karuna Therapeutics, Inc.)是一家處於臨床階段的生物製藥公司,為患有精神和神經系統疾病的人們創造和提供變革性的藥物。其主要產品候選藥物是KarXT,這是一種口服肌膽鹼受體調節劑,正處於III期臨床試驗階段,用於治療精神分裂症患者的急性精神病,以及治療中樞神經系統疾病,如精神分裂症和精神病的負性症狀和認知症狀,以及治療與癡呆相關的精神病。該公司還專注於開發其他針對肌膽鹼的藥物候選品。卡魯納治療公司與Eli Lilly and Company、Zai Lab (Shanghai) Co., Ltd.簽有許可協議,與PureTech Health LLC簽有專利許可協議,並與Charles River Laboratories有藥物發現合作夥伴關係,以及與PsychoGenics, Inc.有藥物發現合作。該公司曾名為Karuna Pharmaceuticals, Inc.,於2019年3月更名為Karuna Therapeutics, Inc.。該公司成立於2009年,總部位於馬薩諸塞州波士頓。



Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

公司網址

https://www.karunatx.com